Therapeutic Potential of Intravenous Phage as Standalone Therapy for Recurrent Drug-Resistant Urinary Tract Infections

Tram Le; Sue C Nang; Jinxin Zhao; Heidi H Yu; Jian Li; Jason J Gill; Mei Liu; Saima Aslam

doi:10.1128/aac.00037-23

Therapeutic Potential of Intravenous Phage as Standalone Therapy for Recurrent Drug-Resistant Urinary Tract Infections

Antimicrob Agents Chemother. 2023 Apr 18;67(4):e0003723. doi: 10.1128/aac.00037-23. Epub 2023 Mar 28.

Authors

Tram Le^#^{1

2}, Sue C Nang^#³, Jinxin Zhao³, Heidi H Yu³, Jian Li³, Jason J Gill^{1

4}, Mei Liu^{1

2}, Saima Aslam^{5

6}

Affiliations

¹ Center for Phage Technology, Texas A&M AgriLife Research, Texas A&M University, College Station, Texas, USA.
² Department of Biochemistry and Biophysics, Texas A&M University, College Station, Texas, USA.
³ Biomedicine Discovery Institute, Infection Program and Department of Microbiology, Monash University, Melbourne, Victoria, Australia.
⁴ Department of Animal Science, Texas A&M University, College Station, Texas, USA.
⁵ Division of Infectious Diseases and Global Public Health, Department of Medicine, University of California San Diego, La Jolla, California, USA.
⁶ Center for Innovative Phage Applications and Therapeutics, University of California San Diego, La Jolla, California, USA.

^# Contributed equally.

Abstract

Recurrent urinary tract infections (rUTI) are common in kidney transplant recipients (KTR) and are associated with multidrug resistance and increased morbidity/mortality. Novel antibiotic alternatives to reduce UTI recurrence are critically needed. We describe a case of rUTI due to extended spectrum beta lactamase (ESBL) Klebsiella pneumoniae in a KTR that was treated successfully with 4 weeks of adjunctive intravenous bacteriophage therapy alone, without concomitant antibiotics, and with no recurrence in a year of follow-up.

Keywords: ESBL; bacteriophage; kidney transplant; phage; rUTI.

Publication types

Case Reports
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't

MeSH terms

Anti-Bacterial Agents / therapeutic use
Humans
Klebsiella pneumoniae
Retrospective Studies
Urinary Tract Infections* / drug therapy
beta-Lactamases* / therapeutic use

Substances

beta-Lactamases
Anti-Bacterial Agents

Abstract

Publication types

MeSH terms

Substances

Grants and funding